European Medicines Agency reviews cardiovascular risk of Multaq

View source ↗

Summary

The European Medicines Agency is reviewing cardiovascular risk associated with Multaq (dronedarone) to assess safety in patients with atrial fibrillation and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Multaq (dronedarone)